IL132269A0 - Process and intermediates for a beta3-adrenergic receptor agonist - Google Patents
Process and intermediates for a beta3-adrenergic receptor agonistInfo
- Publication number
- IL132269A0 IL132269A0 IL13226999A IL13226999A IL132269A0 IL 132269 A0 IL132269 A0 IL 132269A0 IL 13226999 A IL13226999 A IL 13226999A IL 13226999 A IL13226999 A IL 13226999A IL 132269 A0 IL132269 A0 IL 132269A0
- Authority
- IL
- Israel
- Prior art keywords
- intermediates
- receptor agonist
- adrenergic receptor
- beta3
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10437598P | 1998-10-15 | 1998-10-15 | |
| US14546099P | 1999-07-23 | 1999-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL132269A0 true IL132269A0 (en) | 2001-03-19 |
Family
ID=26801476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13226999A IL132269A0 (en) | 1998-10-15 | 1999-10-07 | Process and intermediates for a beta3-adrenergic receptor agonist |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6090942A (fr) |
| EP (1) | EP0994105B1 (fr) |
| JP (1) | JP2000128864A (fr) |
| KR (1) | KR20000029108A (fr) |
| CN (1) | CN1256276A (fr) |
| AT (1) | ATE312821T1 (fr) |
| BR (1) | BR9904689A (fr) |
| CA (1) | CA2285914C (fr) |
| DE (1) | DE69928890D1 (fr) |
| HU (1) | HUP9903602A2 (fr) |
| ID (1) | ID23360A (fr) |
| IL (1) | IL132269A0 (fr) |
| PL (1) | PL336053A1 (fr) |
| TR (1) | TR199902565A2 (fr) |
| YU (1) | YU51599A (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010102198A (ko) | 1999-02-16 | 2001-11-15 | 후루타 타케시 | 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법 |
| US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| ES2228413T3 (es) * | 1999-07-23 | 2005-04-16 | Pfizer Products Inc. | Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos. |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| WO2003072573A1 (fr) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Formes cristallines de (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| MXPA04008298A (es) | 2002-02-27 | 2004-11-26 | Pfizer Prod Inc | Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico. |
| EP1477167A1 (fr) * | 2003-05-15 | 2004-11-17 | Pfizer Limited | Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996035671A1 (fr) * | 1995-05-10 | 1996-11-14 | Pfizer Inc. | AGONISTES DU RECEPTEUR β-ADRENERGIQUE |
| WO1996035670A1 (fr) * | 1995-05-10 | 1996-11-14 | Pfizer Inc. | AGONISTES DU RECEPTEUR β-ADRENERGIQUE |
| GB2305665A (en) * | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
| BR9712951A (pt) * | 1996-11-14 | 1999-12-07 | Pfizer | Processo para piridinas substituìdas |
| US6001856A (en) * | 1997-06-13 | 1999-12-14 | Pfizer Inc. | β-adrenergic agonists to reduce a wasting condition |
| EP0920864A1 (fr) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne |
-
1999
- 1999-09-29 US US09/408,998 patent/US6090942A/en not_active Expired - Fee Related
- 1999-10-07 IL IL13226999A patent/IL132269A0/xx unknown
- 1999-10-08 YU YU51599A patent/YU51599A/sh unknown
- 1999-10-11 DE DE69928890T patent/DE69928890D1/de not_active Expired - Lifetime
- 1999-10-11 EP EP99307987A patent/EP0994105B1/fr not_active Expired - Lifetime
- 1999-10-11 AT AT99307987T patent/ATE312821T1/de not_active IP Right Cessation
- 1999-10-13 ID IDP990951D patent/ID23360A/id unknown
- 1999-10-13 CA CA002285914A patent/CA2285914C/fr not_active Expired - Fee Related
- 1999-10-14 TR TR1999/02565A patent/TR199902565A2/xx unknown
- 1999-10-14 HU HU9903602A patent/HUP9903602A2/hu unknown
- 1999-10-15 KR KR1019990044778A patent/KR20000029108A/ko not_active Application Discontinuation
- 1999-10-15 CN CN99125439A patent/CN1256276A/zh active Pending
- 1999-10-15 JP JP11293733A patent/JP2000128864A/ja active Pending
- 1999-10-15 BR BR9904689-0A patent/BR9904689A/pt not_active IP Right Cessation
- 1999-10-15 PL PL99336053A patent/PL336053A1/xx not_active Application Discontinuation
-
2000
- 2000-01-20 US US09/488,245 patent/US6124457A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HU9903602D0 (en) | 1999-12-28 |
| EP0994105A2 (fr) | 2000-04-19 |
| US6124457A (en) | 2000-09-26 |
| US6090942A (en) | 2000-07-18 |
| CA2285914A1 (fr) | 2000-04-15 |
| TR199902565A2 (xx) | 2000-05-22 |
| HUP9903602A2 (en) | 2001-03-28 |
| BR9904689A (pt) | 2000-11-14 |
| KR20000029108A (ko) | 2000-05-25 |
| PL336053A1 (en) | 2000-04-25 |
| JP2000128864A (ja) | 2000-05-09 |
| YU51599A (sh) | 2001-03-07 |
| EP0994105A3 (fr) | 2000-05-24 |
| EP0994105B1 (fr) | 2005-12-14 |
| ATE312821T1 (de) | 2005-12-15 |
| DE69928890D1 (de) | 2006-01-19 |
| ID23360A (id) | 2000-04-20 |
| CN1256276A (zh) | 2000-06-14 |
| CA2285914C (fr) | 2003-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1052687A1 (en) | Preparation of a camptothecin derivative by intramolecular cyclisation. | |
| IL132269A0 (en) | Process and intermediates for a beta3-adrenergic receptor agonist | |
| PL296651A1 (en) | Method of obtaining novel substituted derivatives of 1,2,3,4-tetrahydrocyclopenta (b)-indole | |
| BG105766A (en) | New process for preparing pesticidal intermediates | |
| IL146811A0 (en) | Novel method for preparing benzoperhydroisoindole compounds | |
| BG106002A (en) | Process for preparing pesticidal intermediates | |
| BR9503845A (pt) | Processo para a preparação de um composto e composto obtido | |
| ZA200005110B (en) | Process for preparing intermediates. | |
| DE69724216D1 (de) | Pyridin-Zwischenprodukte, verwendbar zur Herstellung von Beta-adrenergischen Rezeptor-Agonisten | |
| PL352455A1 (en) | Method of obtaining midodrin hydrochloride | |
| TW429249B (en) | Process for production a novel N-substituted pyrrolidine derivatives | |
| MY120806A (en) | Improved process for preparing pharmaceutically valuable norbenzomorphane derivatives. | |
| MY115259A (en) | Process for the preparation of nmda antagonists | |
| IL135533A0 (en) | Process for the preparing a 1,1,1-trifluoro -2- aminoalkane | |
| WO2000012472A3 (fr) | Procede de preparation de certains composes de phenyluree |